AstraZeneca Reports Phase III Results for BREZTRI in Asthma
WILMINGTON, DE — AstraZeneca (NYSE: AZN) said full results from the Phase III KALOS and LOGOS trials, published in The Lancet Respiratory Medicine, showed its triple-combination inhaler BREZTRI Aerosphere significantly …
AstraZeneca Reports Phase III Results for BREZTRI in Asthma Read More